Data News > Biotechnology and Gene Therapy: Top gainers REGN, CRSP, ALNY, GILD, GSK
REGN is trading UP for the last 1 days, and it at trading at $599.24 with volume of 1,242,740 and a one day change of $30.33 (5.33%). Regeneron Pharmaceuticals, Inc. has a 52-week low of 538.00 and a 52-week high of $1,209.65. The business's 50-day moving average price is $640.61 and its 200 day moving average price is $846.00. The firm has a market cap of $60 million, a P/E ratio of 28.73, and a beta of 0.44.
For more information on REGN:
Historical Price Targets Hiistorical Analyst Recommendations Earning Price Impact Analysis Seasonality Analysis
CRSP is trading UP for the last 1 days, and it at trading at $38.83 with volume of 1,791,392 and a one day change of $1.43 (3.82%). CRISPR Therapeutics AG has a 52-week low of 30.56 and a 52-week high of $67.88. The business's 50-day moving average price is $40.49 and its 200 day moving average price is $45.52. The firm has a market cap of $3 million, a P/E ratio of 14.17, and a beta of 1.84.
Iovance Biotherapeutics (IOVA -1.52%) and CRISPR Therapeutics (CRSP -1.27%) are two incredibly innovative biotechs, but this hasn't translated into strong performances recently. Both stocks have significantly lagged the market over the past three years due to a combination of factors.
For more information on CRSP:
Historical Price Targets Hiistorical Analyst Recommendations Earning Price Impact Analysis Seasonality Analysis
ALNY is trading UP for the last 7 days, and it at trading at $263.49 with volume of 668,181 and a one day change of $6.30 (2.45%). Alnylam Pharmaceuticals, Inc. has a 52-week low of 144.21 and a 52-week high of $304.39. The business's 50-day moving average price is $248.54 and its 200 day moving average price is $258.67. The firm has a market cap of $30 million, a P/E ratio of 0.00, and a beta of 0.30.
For more information on ALNY:
Historical Price Targets Hiistorical Analyst Recommendations Earning Price Impact Analysis Seasonality Analysis
GILD is trading UP for the last 1 days, and it at trading at $106.61 with volume of 5,481,749 and a one day change of $2.40 (2.30%). Gilead Sciences, Inc. has a 52-week low of 60.45 and a 52-week high of $119.12. The business's 50-day moving average price is $108.99 and its 200 day moving average price is $91.01. The firm has a market cap of $130 million, a P/E ratio of 183.22, and a beta of 0.34.
GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the oncology business is under pressure. Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
For more information on GILD:
Historical Price Targets Hiistorical Analyst Recommendations Earning Price Impact Analysis Seasonality Analysis
GSK is trading UP for the last 3 days, and it at trading at $39.87 with volume of 7,188,478 and a one day change of $0.90 (2.30%). GSK plc has a 52-week low of 31.88 and a 52-week high of $44.42. The business's 50-day moving average price is $37.65 and its 200 day moving average price is $37.15. The firm has a market cap of $73 million, a P/E ratio of 16.57, and a beta of 0.30.
GSK reports mixed first-quarter 2025 results. Shares rise in pre-market after it reaffirms guidance and says it is "well positioned" to handle the U.S. tariffs. GSK plc (NYSE:GSK ) Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ET Company Participants Constantin Fest - Head of IR Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Julie Brown - CFO David Redfern - President Corporate Development Tony Wood - Chief Scientific Officer Conference Call Participants James Gordon - JP Morgan Kerry Holford - Berenberg Jo Walton - UBS Graham Parry - Bank of America Simon Baker - Redburn Rajan Sharma - Goldman Sachs Sarita Kapila - Morgan Stanley Constantin Fest Ladies and gentlemen, a very warm welcome to this GSK Q1 2025 Results Call. My name is Constantin Fest, new head of IR at GSK, and I'm delighted to be joined today by Emma Walmsley, Luke Miels and Julie Brown. Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. The Cervarix market report offers a comprehensive analysis of market size, growth potential, and segmentation, highlighting trends across major regions. Key drivers include rising HPV awareness, vaccination rates, and global immunization programs. GSK plc leads the market, with Cervarix targeting HPV-linked conditions like cervical cancer. Advanced HPV vaccines and personalized immunization strategies are emerging trends. The report details market dynamics, historical data, and future growth projections. The Cervarix market report offers a comprehensive analysis of market size, growth potential, and segmentation, highlighting trends across major regions. Key drivers include rising HPV awareness, vaccination rates, and global immunization programs. GSK plc leads the market, with Cervarix targeting HPV-linked conditions like cervical cancer. Advanced HPV vaccines and personalized immunization strategies are emerging trends. The report details market dynamics, historical data, and future growth projections. On Wednesday, British multinational pharmaceutical GSK Plc GSK reported first-quarter sales of $9.46 billion (7.52 billion Sterling Pounds), up 2% year-over-year and 4% on constant currency. Analysts had estimated sales of $7.46 billion.
For more information on GSK:
Historical Price Targets Hiistorical Analyst Recommendations Earning Price Impact Analysis Seasonality Analysis
Biotechnology and Gene Therapy: Top gainers REGN, CRSP, ALNY, GILD, GSK
By KlickAnalytics Data Insights | April 30, 2025 04:38PM ET
Following are the Top 5 companies based on their one-day percentage change within the 'Biotechnology and Gene Therapy' theme.
Regeneron Pharmaceuticals, Inc. (REGN)
REGN is trading UP for the last 1 days, and it at trading at $599.24 with volume of 1,242,740 and a one day change of $30.33 (5.33%). Regeneron Pharmaceuticals, Inc. has a 52-week low of 538.00 and a 52-week high of $1,209.65. The business's 50-day moving average price is $640.61 and its 200 day moving average price is $846.00. The firm has a market cap of $60 million, a P/E ratio of 28.73, and a beta of 0.44.
For more information on REGN:
CRISPR Therapeutics AG (CRSP)
CRSP is trading UP for the last 1 days, and it at trading at $38.83 with volume of 1,791,392 and a one day change of $1.43 (3.82%). CRISPR Therapeutics AG has a 52-week low of 30.56 and a 52-week high of $67.88. The business's 50-day moving average price is $40.49 and its 200 day moving average price is $45.52. The firm has a market cap of $3 million, a P/E ratio of 14.17, and a beta of 1.84.
Top news headlines for CRSP
For more information on CRSP:
Alnylam Pharmaceuticals, Inc. (ALNY)
ALNY is trading UP for the last 7 days, and it at trading at $263.49 with volume of 668,181 and a one day change of $6.30 (2.45%). Alnylam Pharmaceuticals, Inc. has a 52-week low of 144.21 and a 52-week high of $304.39. The business's 50-day moving average price is $248.54 and its 200 day moving average price is $258.67. The firm has a market cap of $30 million, a P/E ratio of 0.00, and a beta of 0.30.
For more information on ALNY:
Gilead Sciences, Inc. (GILD)
GILD is trading UP for the last 1 days, and it at trading at $106.61 with volume of 5,481,749 and a one day change of $2.40 (2.30%). Gilead Sciences, Inc. has a 52-week low of 60.45 and a 52-week high of $119.12. The business's 50-day moving average price is $108.99 and its 200 day moving average price is $91.01. The firm has a market cap of $130 million, a P/E ratio of 183.22, and a beta of 0.34.
Top news headlines for GILD
For more information on GILD:
GSK plc (GSK)
GSK is trading UP for the last 3 days, and it at trading at $39.87 with volume of 7,188,478 and a one day change of $0.90 (2.30%). GSK plc has a 52-week low of 31.88 and a 52-week high of $44.42. The business's 50-day moving average price is $37.65 and its 200 day moving average price is $37.15. The firm has a market cap of $73 million, a P/E ratio of 16.57, and a beta of 0.30.
Top news headlines for GSK
For more information on GSK:
This article was generated by KlickAnalytics data insight content engine.
To view full story, Upgrade to PRO plan!
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.